MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biomarkers

Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Oncotarget 2017 August [Link] Wang LM, Shi ZW, Wang JL, Lv Z, Du FB, Yang QB, Wang Y Abstract BACKGROUND: Conventional measurements are not always helpful in the diagnosis of malignant mesothelioma (MM). Increasing studies indicate that loss of BRCA1-associated protein 1 (BAP1) detected by immunohistochemistry (IHC) is a useful diagnostic marker for MM. In […]

Comments Off on Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.

PLoS One 2017 October [Link] Otoshi T, Kataoka Y, Ikegaki S, Saito E, Matsumoto H, Kaku S, Shimada M, Hirabayashi M Abstract In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, soluble mesothelin-related peptide (SMRP), cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), and the utility of […]

Comments Off on Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Comments Off on Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.

Annals of Oncology 2017 September [Epub ahead of print] [Link] Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struijs EA, Perrino M, Jansen G, Matherly LH, Peters GJ Abstract BACKGROUND: Thymidylate synthase (TS) has a predictive role in pemetrexed-treatment of mesothelioma, however additional chemoresistance mechanisms […]

Comments Off on Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.

Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?

Oncotarget 2017 May [Link] Lagniau S, Lamote K, van Meerbeeck JP, Vermaelen KY Abstract Early diagnosis of malignant pleural mesothelioma (MPM) is a challenge for clinicians. The disease is usually detected in an advanced stage which precludes curative treatment. We assume that only new and non-invasive biomarkers allowing earlier detection will result in better patient […]

Comments Off on Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?

Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma

Modern Pathology 2017 September [Epub ahead of print] [Link] Vivero M, Bueno R, Chirieac LR Abstract Pleural diffuse malignant mesothelioma typically presents during the seventh decade of life and has poor prognosis. Recent epidemiologic studies have shown differences between young and older mesothelioma patients, but the biology of pleural mesothelioma in young patients is poorly […]

Comments Off on Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma

The epithelioid, BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma

Histopathology 2017 September [Epub ahead of print] [Link] Chou A1, Toon CW1, Clarkson A1, Sheen A, Sioson L1 Gill AJ Abstract AIMS: Mesothelioma is a relatively uncommon but highly malignant neoplasm. Most patients die of disease within one year of diagnosis, but some have prolonged survival. Prospective identification of these longer-term survivors may help guide […]

Comments Off on The epithelioid, BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma

Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Human Pathology 2017 August 12 [Epub ahead of print] [Link] Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, OkoĊ„ K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M Abstract Diffuse malignant mesothelioma of the pleura is a highly aggressive tumor typically associated with short survival. […]

Comments Off on Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Evaluating the effect of immune cells on the outcome of patients with mesothelioma

British Journal of Cancer 2017 August 17 [Epub ahead of print] [Link] Chee SJ, Lopez M, Mellows T3, Gankande S, Moutasim KA, Harris S, Clarke J, Vijayanand P, Thomas GJ1, Ottensmeier CH Abstract BACKGROUND: We systematically assessed the prognostic and predictive value of infiltrating adaptive and innate immune cells in a large cohort of patients […]

Comments Off on Evaluating the effect of immune cells on the outcome of patients with mesothelioma

MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study

Disease Markers 2017 [Epub July 3] [Link] Mozzoni P, Ampollini L, Goldoni M, Alinovi R, Tiseo M, Gnetti L, Carbognani P, Rusca M, Mutti A, Percesepe A, Corradi Abstract BACKGROUND: The identification of diagnostic/prognostic biomarkers for asbestos-related diseases is relevant for early diagnosis and patient survival and may contribute to understanding the molecular mechanisms underlying […]

Comments Off on MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study